Group 1 - The major shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., held 8,485,931 shares of Jiahe Meikang, accounting for 6.17% of the total shares before the reduction plan [2] - The reduction plan was announced on September 5, 2025, with a maximum reduction of 1,375,855 shares, or 1% of the total share capital, planned to be executed from October 9, 2025, over a period of three months [3] - The reduction plan period has ended, and Hongyun Jiukang did not execute any share reductions during this time due to liquidity needs and market conditions [4] Group 2 - The company confirmed that the reduction plan was in compliance with relevant laws and regulations, and there were no violations of the plan or other commitments [4] - The actual reduction did not meet the minimum reduction quantity as per the initial plan, and the plan was not terminated early [4]

Core Viewpoint - The announcement from Jiahe Meikang indicates that its shareholder Hongyun Jiukang plans to reduce its stake due to liquidity needs, but ultimately did not execute the planned share reduction within the specified timeframe [2] Group 1: Shareholder Information - Hongyun Jiukang held 8,485,931 shares of Jiahe Meikang, representing 6.17% of the total shares before the reduction plan [2] - The planned reduction was set to occur from October 9, 2025, for a period of three months, with a maximum of 1,375,855 shares to be sold, equating to no more than 1% of the total share capital [2] Group 2: Reduction Plan Outcome - The reduction plan's timeframe ended on January 8, 2026, during which Hongyun Jiukang did not sell any shares of Jiahe Meikang [2]

Core Viewpoint - Jiahe Meikang (688246.SH) has received a notification from Hongyun Jiukang regarding the results of its share reduction plan, indicating that no shares were reduced during the specified period from October 9, 2025, to January 8, 2026 [1] Group 1 - The share reduction plan's time frame has now expired without any shares being sold [1]

证券代码：688246 证券简称：嘉和美康 公告编号：2026-001 嘉和美康（北京）科技股份有限公司 持股 5%以上股东减持计划时间届满 暨未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，嘉和美康（北京）科技股份有限公司（以下简"嘉和 美康"或"公司"）股东弘云久康数据技术（北京）有限公司（以下简称"弘云 久康"）持有公司股份 8,485,931 股，占公司股份总数的 6.17%。上述股份为嘉 和美康首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流 通。 减持计划的实施结果情况 公司于 2025 年 9 月 5 日披露了《嘉和美康持股 5%以上股东减持股份计划公 告》（公告编号：2025-061），弘云久康因自身流动性需求，计划自 2025 年 10 月9日起3个月内根据市场情况通过集中竞价方式减持其持有的公司股份合计不 超过 1,375,855 股，即不超过公司总股本的 1%。 公司于近日收到弘 ...

嘉和美康公告称，股东弘云久康在减持计划实施前持有公司8485931股，占比6.17%。2025年9月5日， 公司披露弘云久康减持计划，拟自2025年10月9日起3个月内，通过集中竞价减持不超1375855股，即不 超总股本1%。2025年10月9日至2026年1月8日，弘云久康未减持公司股份，减持计划时间区间届满，目 前仍持股8485931股，占比6.17%。 ...

Core Viewpoint - The DRG/DIP concept has seen a significant increase of 5.67%, ranking third among concept sectors, with 21 stocks rising, including a 20% surge in Di'an Diagnostics, and several other stocks reaching their daily limit up [1][2]. Group 1: Market Performance - The DRG/DIP concept sector experienced a net inflow of 350 million yuan, with 14 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2]. - Di'an Diagnostics led the net inflow with 290 million yuan, followed by Jiuyuan Yinhai and Guoxin Health with net inflows of 206 million yuan and 127 million yuan, respectively [2][3]. Group 2: Stock Performance - The top performers in the DRG/DIP concept included: - Di'an Diagnostics with a 20% increase and a turnover rate of 20.80% [3]. - Jiuyuan Yinhai with a 10.02% increase and a turnover rate of 10.61% [3]. - Guoxin Health with a 10.01% increase and a turnover rate of 2.90% [3]. - Other notable stocks include: - Weining Health with a 13.79% increase and a turnover rate of 18.16% [4]. - Jiahe Meikang with an 11.17% increase and a turnover rate of 13.98% [3].

Group 1 - The core point of the news is that Jiahe Meikang's stock price has dropped by 5.07%, currently trading at 23.05 yuan per share, with a total market capitalization of 3.171 billion yuan [1] - Jiahe Meikang (Beijing) Technology Co., Ltd. was established on March 3, 2006, and went public on December 14, 2021. The company specializes in the research and industrialization of medical information software [1] - The revenue composition of Jiahe Meikang includes: software development and technical services (42.39%), self-developed software sales (37.64%), purchased software and hardware sales (19.86%), and other service sales (0.11%) [1] Group 2 - From the perspective of fund holdings, one fund under Taixin Fund has Jiahe Meikang as a major holding. The Taixin Internet + Theme Mixed A Fund (001978) held 6,947 shares in the third quarter, accounting for 4.93% of the fund's net value, making it the largest holding [2] - The Taixin Internet + Theme Mixed A Fund (001978) was established on June 8, 2016, with a latest scale of 4.2898 million. It has experienced a loss of 6.04% this year, ranking 8,110 out of 8,159 in its category [2] - The fund manager of Taixin Internet + Theme Mixed A is Chen Ying, who has been in the position for 3 years and 348 days, with a total asset scale of 540 million yuan. The best fund return during the tenure is 15.67%, while the worst is -14.68% [3]

Group 1 - The core viewpoint of the news is that 嘉和美康 (Jiahe Meikang) experienced a decline in stock price and significant changes in financing and shareholder structure, indicating potential challenges in its financial performance and market position [1][2]. Group 2 - On December 24, 嘉和美康's stock fell by 2.41%, with a trading volume of 119 million yuan. The financing data showed a net financing outflow of 1.46 million yuan, with a total financing balance of 186 million yuan, accounting for 5.64% of the circulating market value [1]. - The company’s financing balance is above the 70th percentile of the past year, indicating a relatively high level of financing activity [1]. - 嘉和美康's short selling data on December 24 showed no shares were sold or repaid, with a short selling balance of 13,500 shares, which is above the 90th percentile of the past year [1]. - As of November 10, 嘉和美康 had 8,866 shareholders, an increase of 16.78%, while the average number of circulating shares per shareholder decreased by 14.37% [2]. - For the period from January to September 2025, 嘉和美康 reported a revenue of 330 million yuan, a year-on-year decrease of 30.67%, and a net profit attributable to shareholders of -174 million yuan, a significant decline of 320.68% [2]. - Among the top ten circulating shareholders, 长城消费增值混合A (Changcheng Consumption Value Mixed A) held 2.00 million shares, a decrease of 410,000 shares compared to the previous period [2].

Group 1 - The core viewpoint of the news is that 嘉和美康 experienced a significant decline in stock price and financial performance, indicating potential challenges for the company [1][2]. Group 2 - On December 23, 嘉和美康's stock price dropped by 5.15%, with a trading volume of 145 million yuan. The financing data showed a net financing outflow of 770,700 yuan for the day [1]. - As of December 23, 嘉和美康's total margin trading balance was 187 million yuan, accounting for 5.55% of its market capitalization, which is above the 80th percentile of the past year [1]. - The company had no short selling activity on December 23, with a short selling balance of 331,000 yuan, also above the 90th percentile of the past year [1]. - 嘉和美康's main business includes medical information software development and commercialization, with revenue composition being 42.39% from software development and technical services, 37.64% from self-developed software sales, and 19.86% from purchased software and hardware sales [1]. Group 3 - As of November 10, 嘉和美康 had 8,866 shareholders, an increase of 16.78%, while the average circulating shares per person decreased by 14.37% [2]. - For the period from January to September 2025, 嘉和美康 reported a revenue of 330 million yuan, a year-on-year decrease of 30.67%, and a net profit attributable to shareholders of -174 million yuan, a year-on-year decrease of 320.68% [2]. - Among the top ten circulating shareholders as of September 30, 2025, 长城消费增值混合A held 2.001 million shares, a decrease of 410,000 shares compared to the previous period [2].

Group 1 - The core point of the news is that Jiahe Meikang's stock price dropped by 5.03% to 24.52 yuan per share, with a trading volume of 1.23 billion yuan and a turnover rate of 3.56%, resulting in a total market capitalization of 3.374 billion yuan [1] - Jiahe Meikang (Beijing) Technology Co., Ltd. was established on March 3, 2006, and went public on December 14, 2021. The company specializes in the research and industrialization of medical information software [1] - The revenue composition of Jiahe Meikang includes software development and technical services at 42.39%, self-developed software sales at 37.64%, purchased software and hardware sales at 19.86%, and other service sales at 0.11% [1] Group 2 - From the perspective of major fund holdings, the Guoxin Guozheng Fund has one fund heavily invested in Jiahe Meikang. The Guoxin Guozheng Xinli A (001797) held 9,000 shares in the third quarter, unchanged from the previous period, accounting for 1.26% of the fund's net value, ranking as the eighth largest holding [2] - The Guoxin Guozheng Xinli A (001797) was established on September 2, 2015, with a latest scale of 20.6671 million. Year-to-date returns are 11.34%, ranking 5,539 out of 8,088 in its category; the one-year return is 9.78%, ranking 5,659 out of 8,057; and since inception, it has incurred a loss of 13.6% [2]